All In Biotech

Drug Trial Radar · NCT05011851

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

Last checked: Nov 20, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

Jul 12, 2022

Primary completion

May 13, 2024

Study completion Jul 16, 2024

Sponsor

Lead sponsor
Neuren Pharmaceuticals LimitedIndustry
Sponsor type
Industry
First posted
Aug 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome

Conditions

  • Angelman Syndrome

Interventions

  • NNZ-2591Drug

    NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 13 weeks
  2. Pharmacokinetic - Typical AUC24 of 30kg ChildTime frame: 13 weeks
  3. Pharmacokinetic - Typical t1/2 in 30 kg ChildTime frame: 13 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sydney Children's Hospital

    Randwick, New South Wales, Australia

  • Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service

    South Brisbane, Queensland, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.